Will Canopy Growth Corp (TSX:WEED) Hit $100 This Year?

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) has been generating a lot of hype once again now that investors have gotten a glimpse of the company’s big plans for the U.S. market.

| More on:
question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canopy Growth (TSX:WEED)(NYSE:CGC) has been on the rise again. Last week, the stock closed at over $67 — the last time it did that was back in late January. The last time the share price closed at over $70 was back in October, right around legalization and before pot stocks took a big hit.

Now, with news of Canopy Growth having a deal in place for a big U.S. company, and with it looking to expand its operations south of the border, investors are feeling very bullish about the stock once more. The big question for me is whether there’s enough excitement surrounding the stock to push it to the $100 mark.

Let’s take a look at why it might happen as well as why it might not.

How Canopy Growth could reach $100

By no means am I going to say that Canopy Growth is a cheap stock. Currently, it trades at around 150 times its sales, and investors have proven they are willing to pay big premiums for the top pot stock in the industry. However, that’s actually a lower multiple than what other stocks in the industry are trading at. If Canopy Growth is simply able to generate more hype around it and trade at a multiple of more than 220 times its sales, that would mean the stock would be trading at $100 per share.

That would require a lot of speculators to bid up the stock, and given how volatile marijuana stocks have been lately, it’s not something I would expect on happening any time soon. However, with the company releasing its quarterly earnings soon, we’re likely to see another big boost in sales in what will be Canopy Growth’s first full quarter of the recreational pot market being open for business.

Even if the company simply matches last quarter’s performance with $83 million in revenue, that will be a $60 million increase from the prior year and put its trailing 12 months sales at $215 million. If the stock continues to trade at around 150 times earnings, a higher sales number would put it close to $100.

Why the stock might not reach $100

Even if Canopy Growth has a solid quarter, investors may not be willing to pay such high multiples to sales on cannabis stocks. With there still being a lot of uncertainty surrounding the industry in both Canada and the U.S., we saw investors cool off of marijuana stocks late last year. And although we’ve seen rallies happen since then, over the long term the sustainability might not be there.

For Canopy Growth to reach $100 and not split its shares, that would mean its market cap would be north of $34 billion, putting it right around where blue-chip stocks like Rogers and Telus are currently being valued. Shopify, which has generated a lot of sales over the years and been one of the hottest stocks on the TSX, could end up being valued lower than Canopy Growth if the pot stock would soar to those heights. I would expect there to be a lot of resistance from investors to prevent Canopy Growth from getting so big, as the aforementioned stocks have very strong track records and have generated a lot more in sales to warrant those high valuations.

Bottom line

Even with a good quarter, I wouldn’t expect Canopy Growth to reach $100 this year. Investors have been a bit more hesitant on pot stocks lately, and it’s important to note that although they’ve recovered, they’ve yet to reach the peaks of last year, and that’s with sales being much stronger.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned. Tom Gardner owns shares of Shopify. The Motley Fool owns shares of Shopify and Shopify. Shopify is a recommendation of Stock Advisor Canada.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »